Kết quả lâm sàng phác đồ kích thích buồng trứng sử dụng progestin so với phác đồ Antagonist trên bệnh nhân chuyển đơn phôi đông lạnh ngày 5

Abstract

This retrospective descriptive study included 305 patients undergoing in vitro fertilization (IVF), who were divided into two groups: 157 patients received the progestin-primed ovarian stimulation (PPOS) protocol and 148 patients received the antagonist protocol, followed by single day-5 frozen embryo transfer. The two groups were similar in baseline clinical characteristics, including age, duration of infertility, BMI, ovarian reserve markers (AMH, AFC), and baseline hormonal profile (FSH, LH). The total FSH dose and duration of ovarian stimulation were not significantly different between the two groups (p > 0.05). Estradiol and LH levels on the trigger day were higher in the PPOS group (p < 0.05), but no case of premature ovulation was recorded. Embryo quality on day 5 prior to transfer was similar between the two groups. Clinical outcomes, including positive β-hCG rate (61.78% vs. 62.16%, p > 0.05), clinical pregnancy rate (52.87% vs. 52.70%, p > 0.05), ongoing pregnancy rate (51.59% vs. 50.68%, p > 0.05), and live birth rate (49.04% vs. 48.65%, p > 0.05), showed no statistically significant difference between the PPOS and antagonist groups. These findings suggest that the PPOS protocol provides clinical outcomes similar to the GnRH antagonist protocol and represents a feasible alternative in IVF cycles employing a freeze-all strategy.